NEW YORK, Sept. 20, 2024 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease ...

GV20 Therapeutics, a clinical-stage AI-based next generation biotherapeutics company, today announced presentation of ...

Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024WALTHAM, Mass., Sept.

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...

and highlights Signatera’s ability to predict adjuvant chemotherapy (ACT) benefit. Full details on the data are available here, as announced on Sept. 14, 2024. CRC Data from GALAXY (Annals of Oncology ...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...